PCI Biotech with share issue in November

Oslo Cancer Cluster member PCI Biotech has initiated a process with the objective to carry out a share issue in the range of NOK 40-50 million by the end of November 2016. Two of the largest shareholders have pledged that they will at least follow up their pro-rata in the share issue. Fondsfinans is retained as advisors in this process.

 

The promising results from the Phase I part of the Phase I/II study of fimaChem in bile duct cancer and the recently granted orphan designation in EU have provided the Company with new exciting opportunities.  The Company has initiated processes to assess whether a well-designed pivotal Phase II study may provide market authorisation, which would significantly shorten the time to market for this orphan indication.

The proceeds from the contemplated share issue will allow the Company to complete regulatory interactions with European and US authorities, to determine the fastest way to market. The Phase I results have also furnished increased external interest, which will be assessed in relation to various financing and partnering alternatives for further development.

Establishing fimaVacc as a clinical asset in immunotherapy is a major milestone towards commercialisation and the proceeds will also be used to fund completion of the Phase I study. The initiated Phase I study in healthy volunteers is designed to show enhancement of the cellular immune responses important for therapeutic effect of vaccines, with expected read-out of results in the first half of 2017.

The strategy for the fimaNAc programme will continue to be an opportunistic approach, pursuing out-licensing opportunities.

 

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For more information visit: www.pcibiotech.com

 

Successful Nordic Life Science Days 2016

The Nordic Life Science Days 2016 was a great success at many levels. For the first time the Norwegian life science actors invited to a joint meeting to promote a closer collaboration with the Swedish life science milieu at an even t at the Norwegian Embassy in Stockholm. Oslo Cancer Cluster was co-hosting the Nordic Life Science conference this year, and we hosted three super-sessions on oncology which set the scene for the future of oncology treatment.

 

Below you may find a summary of the coverage of our joint activities with UIO:Life Science and LMI at the Nordic Life Science Days, only in Norwegian. We will also like to stress our gratitude towards both Ambassador Kai Eide and his staff at the Noorwegian Embassy in Stockholm and Director for Innovation Anne Kjertsi Fahlvik at the Norwegian Research Council for sponsoring and great collaboration.

 

Kronikk i Dagens medisin 13. september: Livsvitenskap stort potensial for verdiskaping

Med et nordisk samarbeid for klinisk utprøving kan vi stå sterkere i konkurransen om å tiltrekke oss aktører som vil gjennomføre kliniske studier. Dette kan gi nordiske pasienter tilgang til innovativ behandling.

#noswelife

Aktivitet på Twitter fra nettverkskvelden kan på ses på hashtagen #noswelife

https://twitter.com/search?q=%23noswelife&src=typd

Standbesøk

Fra ambassadørens besøk på standen sammen med medsponsor Forskningsrådet
https://twitter.com/forskningsradet/status/776023988204101633

Omtaler på lmi.no

Nordic Life Science Days er i gang i Stockholm

LMI står på stand med flere andre aktører for å promotere Norge og norsk livsvitenskap.
http://www.lmi.no/aktuelt-fra-lmi/2016/09/nordic-life-science-days-er-i-gang-i-stockholm

Trenger Norge en egen koordinator for livsvitenskap?

Det var et av temaene da ambassaden inviterte til nettverkskveld i går.

http://www.lmi.no/aktuelt-fra-lmi/2016/09/trenger-norge-en-egen-koordinator-for-livsvitenskap

Omtaler på uio.no/livsvitenskap

Norsk-svensk nettverkskveld og Nordic Life Science Days

http://www.uio.no/forskning/satsinger/livsvitenskap/aktuelt/aktuelle-saker/2016/norsk-svensk-nettverkskveld-og-nordic-life-science.html

Også sendt med nyhetsbrev til over 1000 abonnenter

http://www.uio.no/forskning/satsinger/livsvitenskap/aktuelt/nyhetsbrev/2016/september.html

Omtaler på norge.se

Vellykket norsk-svensk dialog-kveld om Life Science samarbeid. Norsk-svensk «Helseinnovatørskole» lansert. http://www.norge.se/News_and_events/Nyheter-om-politikk-og-okonomi/Vellykket-norsk-svensk-dialog-kveld-om-Life-Science-samarbeid-Norsk-svensk-Helseinnovatorskole-lansert-/#.V-kZnfmLRaQ

Nordic Life Science Days og norsk-svensk nettverkskveld

  1. og 15. september arrangeres Nordic Life Science Days i Stockholm, Nordens største konferanse for den globale livsvitenskapsindustrien. I tilknytning til konferansen arrangerer Norges ambassade en svensk-norsk dialog og nettverkskveld.

http://www.uio.no/forskning/satsinger/livsvitenskap/aktuelt/nyhetsbrev/2016/september.html

 

PCI Biotech and BioNTech initiates preclinical research collaboration

Oslo Cancer Cluster member PCI Biotech is a cancer focused biopharmaceutical company. They have initiated a preclinical agreement with BioNTech AG, which is a fully integrated biotechnology company developing individualized cancer immunotherapies.

 

The partnership is governed by a preclinical research collaboration agreement. In brief, the preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies performed by the University of Zurich. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership. PCI Biotech has already a collaboration agreement with the University of Zurich and the research is funded through the existing agreement.

Per Walday, CEO of PCI Biotech, said: “I’m very pleased to announce another research agreement in the field of nucleic acid therapeutics. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities. We look forward to explore synergies with BioNTech’s pioneering disruptive technologies.“

 

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.  fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.  fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
About BioNTech AG
BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper® a molecular in-vitro diagnostic kit, marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held, with Strüngmann Family Office as a majority shareholder, having closed the largest initial financing in the European biopharma sector’s history. Information about BioNTech is available at www.biontech.de.

 

Ultimovacs satser sterkt på videre utprøving av lovende kreftvaksine

Kreftvaksineselskapet Ultimovacs AS henter NOK 75 millioner til finansiering av videre kliniske studier. Selskapet har gjennomført tre vellykkede fase I-studier for sin terapeutiske vaksine mot kreft. Over 50 kreftpasienter har deltatt i studiene. Studiene viser at mer enn 80% av pasientene får aktivert sitt immunsystem som følge av denne behandlingen.

Bilde: Administrerende direktør Øyvind Kongstun Arnesen, kreditering: Charlotte Sverdrup

Eksisterende aksjonærer og ansatte bidrar med NOK 55 millioner, mens Watrium AS skyter inn NOK 15 millioner av totalt MNOK 20 millioner fra nye aksjonærer.
«Studiene er relativt små, men gir klare signaler om at vaksinen kan gi positive kliniske effekter for pasientene», sier Øyvind Kongstun Arnesen som er administrerende direktør i Ultimovacs.

I de nye kliniske studiene som skal igangsettes ønsker selskapet å dokumentere at vaksinen kan gi betydelig behandlingsgevinst for kreftpasienter.

Ultimovacs er ett av flere norske selskaper med tilknytning til Oslo Cancer Cluster som ligger langt fremme i utviklingen av nye behandlingsformer mot kreft basert på immunterapi. Norge ligger langt fremme innenfor immunterapi og har et godt grunnlag for å utvikle en næring med internasjonalt potensial. «Vår teknologi, som har sitt utspring fra Radiumhospitalet, kan vise seg å gi et betydelig bidrag i utviklingen av nye metoder for kreftbehandling», sier Øyvind Kongstun Arnesen. Vaksinen vil over de neste 2-3 årene testes ut på mer enn 250 pasienter i flere land.

Ultimovacs har over det siste året styrket sin organisasjon vesentlig og har nå 10 ansatte.
«Vi har et svært kompetent team på plass for videre utprøving og kommersialisering av vaksinen internasjonalt», fortsetter Øyvind Kongstun Arnesen.

Ultimovacs har solide finansielle eiere som Gjelsten Holding AS, Canica AS, Sundt AS og nå kommer også Watrium AS inn som ny aksjonær. I den forbindelse vil Kristin Wilhelmsen fra Watrium tre inn i styret i Ultimovacs. Inven2 AS og Radiumhospitalets Forskningsstiftelse er også betydelige eiere i Ultimovacs.

Ultimovacs er verdsatt til NOK 475 millioner før innhenting av ny kapital. DNB Markets og Arctic Securities har bistått selskapet som finansielle rådgivere og tilretteleggere av transaksjonen.
«Vi er meget tilfreds med å ha en bred sammensetning av kapitalsterke, langsiktige og kompetente eiere som bidrar aktivt til den videre utviklingen av selskapet», sier styreleder Ketil Fjerdingen.

__________________________________________________________________________________

Ultimovacs AS er et norsk selskap som arbeider med å utvikle immunterapi mot kreft i form av en universell, terapeutisk kreftvaksine.  I dag har selskapet 10 ansatte som holder til i Oslo Cancer Cluster Innovasjonspark ved Radiumhospitalet. Selskapet er i ferd med å avslutte sitt fase I-program hvor man har fått data om sikkerhet, valg av dose og vaksinens evne til å aktivere immunsystemet. Med støtte i disse dataene går selskapet nå videre til fase II for å undersøke om vaksinen har positiv effekt på kreftsykdom. Ultimovacs største eiere er Gjelsten Holding AS, Inven2, Radiumhospitalets Forskningsstiftelse, Langøya Invest, Canica AS og Sundt AS.

Photocure with exciting news: FDA-approval of new packaging for bladder cancer product

New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product.

 

Oslo Cancer Cluster member Photocure recently received the positive news that the U.S. Food & Drug Administration (FDA) has granted approval for an improved and more user-friendly packaging for Cysview. Regulatory approval in EU was granted in July 2016.

Diluent for Cysview is used to reconstitute the Cysview powder resulting in the Cysview solution. The diluent that is used to reconstitute the Cysview powder will now be provided in a prefilled syringe and in a needle free kit.

“This improvement is aligned with our mission to provide bladder cancer patients with access to treatments that improve their lives. The new Cysview kit will simplify the clinical use of Cysview both in the use of Blue Light Cystoscopy with Cysview during bladder cancer resection as well as the future launch of Cysview in the outpatient surveillance setting”, says Kjetil Hestdal, M.D., Ph.D., President and CEO, Photocure ASA.

 

 

About Hexvix®/Cysview®
Hexvix®/Cysview® (hexaminolevulinate hydro-chloride) is an innovative breakthrough technology in the diagnosis and management of non-muscle-invasive bladder cancer. It is designed to selectively target malignant cells in the bladder and induce fluorescence during a cystoscopic procedure using a blue light enabled cystoscope. Using Hexvix®/Cysview® as an adjunct to standard white light cystoscopy enables the urologist to better detect and remove lesions, leading to a reduced risk of recurrence.

Hexvix® is the tradename in Europe, Cysview® in U.S. and Canada. Hexvix® is marketed and sold by Photocure in the Nordic countries and in the US with the trade name Cysview®. Photocure has a strategic partnership with Ipsen for the commercialization of Hexvix in Europe, excluding the Nordic region.  Please refer to https://www.photocure.com/Partnering-with-Photocure/Our-partners for further information on our commercial partners.

 

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology® platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, and skin conditions. Our aim is to provide solutions, which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

 

About Bladder Cancer
Bladder cancer is the fifth most common cancer in men with more than 330 000 new cases annually and more than 130 000 die of the disease1. It has a high recurrence rate with an average of 61% in one year and 78% over five years, making the lifetime costs of managing bladder cancer one of the highest amongst all cancers. It is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies because of the high risk of recurrence.

A recent paper on the economic burden of bladder cancer across the European Union estimates that bladder cancer cost the EU 4.9 billion Euro in 2012. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC is still in the inner layer of cells. These cancers are the most common (75%) of all bladder cancer cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.

Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma

Oslo 1 July 2016: Targovax today announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.

 

“New therapies are needed to provide better care for patients with mesothelioma, a highly malignant cancer with poor prognosis” says Dr Magnus Jaderberg, CMO of Targovax. “This clinical trial will provide data to evaluate the efficacy and safety of ONCOS-102 in first and second line mesothelioma patients, and we hope that our immunotherapy can provide additional benefit to chemotherapy, the existing standard of care.,

 

“In addition, treating the first patient in the first oncolytic virus trial of the merged company is of course an exciting moment for Targovax and all its stakeholders” adds Dr Jaderberg.

 

The trial is a randomized phase I/II clinical trial of 30 patients, with a phase Ib safety lead-in cohort of six patients, in first line and second line MPM patients who are eligible for treatment with pemetrexed and cisplatin. The trial’s main objectives are determination of safety, immune activation at lesional level and in peripheral blood, clinical response and the correlation between clinical outcome and the immunological activation. Several investigational sites in Europe will participate in this study. In addition to this trial, Targovax plans to initiate three immunotherapy combination trials with ONCOS-102 and one with its RAS peptide vaccine TG02 during the second half of 2016.

 

Malignant mesothelioma is a rare type of cancer often caused by exposure to asbestos. There are no curative treatments although surgery, chemotherapy and radiotherapy can sometimes help to improve patient prognosis and life expectancy. Pemetrexed and cisplatin is the only standard of care chemotherapy for malignant mesothelioma, but the median PFS/OS (progression-free survival/overall survival) from the initiation of treatment is only approximately 12 months.

 

ONCOS-102 is a purposefully engineered human serotype 5/3 adenovirus coding for human GM-CSF optimized to induce systemic anti-tumor T cell response in cancer patients. In a previous Phase I trial, ONCOS-102 treatment induced tumor specific immune activation both at systemic and lesional level. The immune activation was associated with clinical benefit.

For further information, please contact:

 

Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr@targovax.com

 

Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

 

Arming the patient’s immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

 

ONCOS – 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system’s capacity to recognize and attack cancer cells.

 

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

 

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

Apim, Vaccibody and Targovax will present at ICCS prior to BIO in San Fransisco

Oslo Cancer Cluster will for the 5th time arrange International Cancer Cluster Showcase, ICCS in collaboration with leading cluster partners from Europe and North America. 20 oncology biotechs will pitch their latest innovations and partnering opportunities.

Member companies pitching at ICCS are Apim Therapeutics, Vaccibody and Targovax.

Oslo Cancer Cluster will not feature a booth this year, but International Advisor Jutta Heix will be present at BIO and participate in partnering meetings as well as CEO Ketil Widerberg,

Targovax with encouraging interim results on RAS specific peptide vaccine in resected pancreatic cancer

Oslo Cancer Cluster member Targovax has conducted a predetermined interim analysis of the TG01 Phase I/II trial, indicating promising 1-year overall survival data when combining TG01 with gemcitabine, chemotherapy, as supplementary treatment of patients with pancreatic cancer.

 

Of the 19 patients included in the study, 15 patients provided consent to be followed up for survival and four patients did not provide consent to be followed up. 1-year survival data showed that 14 out of these 15 patient were alive and one passed away due to pneumonia assessed by the investigator as unrelated to the patients underlying cancer.

The regimen was generally well tolerated and RAS specific T-cell immune responses were induced and enhanced when TG01/GM-CSF was administered in combination with gemcitabine (1).

“One must be careful when drawing conclusions from small survival trials, but this result is an encouraging signal of efficacy and we look forward to the two year survival data which is expected during the first half year of next year“, says Gunnar Gårdemyr, CEO of Targovax.

The study is a single arm study of TG01 in combination with standard of care gemcitabine as adjuvant treatment of patients with operable pancreatic cancer. The interim analysis covered 1-year survival of the first cohort of 19 patients.

References: 1-year overall survival in two independent studies of patients with resected adenocarcinoma of the pancreas receiving standard of care gemcitabine were both approximately 75% (2,3).

 

About Targovax: “Arming the patient’s immune system to fight cancer”

Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a leader in its area. The company is currently developing two complementary and highly targeted approaches to immuno-oncology:

ONCOS- 102 is part of a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment may reinstate the immune system’s capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancers and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

The product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in early stage of development. For more information go to www.targovax.com

Norways largest newspaper VG with broad coverage of cancer R&D in Norway

VG_forside_feb

VG, one of Norway´s largest news paper, has issued broad coverage of Norwegian cancer R&D in their paper and online edition. The coverage includes an overview of the cancer treatment being developed by 10 of Oslo Cancer Cluster member companies.

 

IMG_1753 IMG_1756 IMG_1760photocure

15 MNOK to Nordic Nanovector to develop targeted cancer treatments

NNV_bilde

Oslo Cancer Cluster member Nordic Nanovector ASA is awarded of a up to NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme (in Norwegian; Brukerstyrt innovasjonsarena, BIA) to support the research and development of novel targeted therapeutics for leukemia  and non-Hodgkin Lymphoma.

The award is based on the promising potential for value creation, both for patients and the society at large, as well as for Nordic Nanovector together with the high quality of research and innovation and the company’s international ambitions.

Nordic Nanovector’s Chief Scientific Officer, Jostein Dahle, commented: “This grant funding is important as it enables us to advance early stage research that leverages our expertise in ARC therapies, particularly around CD37-targeted approaches, as a means of developing a broader portfolio of products behind Betalutin® for treating malignant leukaemias and lymphomas.”

The grant will be paid over a three-year period. It is assigned to and will enable acceleration of the early stage project entitled “Development of Two New Antibody Radionuclide Conjugates (ARCs) for Treatment of Malignant Lymphoma and Leukemia”. The project is focused on development of ARCs consisting of a chimeric anti-CD37 antibody (chHH1) and a radioactive nuclide as the cytotoxic agent. chHH1 is a humanized version of the murine HH1 antibody, the tumour-targeting component of Nordic Nanovector’s lead candidate Betalutin®, which is currently advancing in a Phase 1/2a clinical trial for the treatment of third line and second line NHL.

Nordic Nanovector will construct and investigate ARCs with different payloads. These combinations have the potential to lead to product candidates with a range of drug profiles that may be applicable across multiple haematological malignancies. Successful candidates are expected to be advanced into clinical trials.

Established in 2006, the BIA programme is the largest industry-oriented programme at the Research Council of Norway (Forskningsrådet).  This broad-based programme supports high-quality R&D projects with good business and socio-economic potential.

 

 

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com